Delivery Order SPE2DB22D9239-SPE2DB25FDL21
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The...
- The Defense Logistics Agency awarded a delivery order valued at $9,114.54 to DMS Pharmaceutical Group Inc. for Perjeta 420 mg/14 ml vials on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order represents a pharmaceutical supply requirement with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is the prime contractor on this award. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth up to $25,529.76 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4563969889 - Perjeta 420 mg/14 ml vial, 14 ml, with a performance period through April 1, 2024. This delivery order is issued under DMS Pharmaceutical Group's indefinite delivery contract SPE2DB24FSW68 with DLA, which has a ceiling value of up to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a firm fixed-price delivery order from the Defense Logistics Agency valued at $4,557.26 for Perjeta 420 mg/14 ml vials. The award, issued on July 31, 2025, with an ultimate completion date of August 21, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $54.7K by the Defense Logistics Agency for the supply of Perjeta 420 mg/14 mL vials. The contract, awarded on July 30, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $27,343.62 on July 28, 2025, for the supply of Perjeta 420 mg/14 mL vials. The contract, which carries no set-aside designation, is funded by the Defense Logistics Agency's Medical Supply Chain and is scheduled for completion by August 18, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order valued at twenty thousand six hundred ninety-two dollars and fifty cents ($20,692.50) by the Defense Logistics Agency to provide Perjeta 420 mg/14 ml vials. This delivery order was issued against DMS Pharmaceutical Group's indefinite delivery contract with the Defense Logistics Agency to supply pharmaceuticals and medical supplies with a potential value of up to five million dollars through December 2025. As a...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to supply the pharmaceutical product Perjeta 420 mg/14 ml vial. The order has a potential value of $8,277.00 and a completion date of January 12, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that provides a range of brand and generic prescription and over-the-counter drug supplies to the federal government, primarily the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $4,254.96 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Perjeta 420 mg/14 ml vials. This order is part of a larger indefinite delivery contract, SPE2DB, valued at up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical products to support the recurring medical supply needs of military health facilities...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB25FDL21Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. on August 19, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, will be performed at the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits as a woman-owned small business pharmaceutical wholesaler. This delivery order is issued under the company's larger Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products for military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. serves as a critical supplier within the federal pharmaceutical supply chain, specializing in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's established relationship with the DLA—evidenced by its substantial IDC—reflects its consistent capability to deliver specialized pharmaceutical products, including oncology treatments and other critical medications, to support military medical operations. This particular delivery of Perjeta, a biologic used in cancer treatment, exemplifies the vendor's role in providing advanced pharmaceutical therapeutics to federal healthcare facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.2k | 8/19/25 |